JP2011507599A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011507599A5 JP2011507599A5 JP2010539515A JP2010539515A JP2011507599A5 JP 2011507599 A5 JP2011507599 A5 JP 2011507599A5 JP 2010539515 A JP2010539515 A JP 2010539515A JP 2010539515 A JP2010539515 A JP 2010539515A JP 2011507599 A5 JP2011507599 A5 JP 2011507599A5
- Authority
- JP
- Japan
- Prior art keywords
- medical device
- connexin
- compound
- item
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 31
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 238000002513 implantation Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 230000006378 damage Effects 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- 238000003780 insertion Methods 0.000 claims description 12
- 230000037431 insertion Effects 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 10
- 239000007943 implant Substances 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 102000001045 Connexin 43 Human genes 0.000 claims description 6
- 108010069241 Connexin 43 Proteins 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 230000002792 vascular Effects 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 230000001668 ameliorated effect Effects 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 108091030071 RNAI Proteins 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 230000003872 anastomosis Effects 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 230000004888 barrier function Effects 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 239000000316 bone substitute Substances 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 238000007598 dipping method Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000009368 gene silencing by RNA Effects 0.000 claims description 2
- 210000005003 heart tissue Anatomy 0.000 claims description 2
- 210000003709 heart valve Anatomy 0.000 claims description 2
- 230000002439 hemostatic effect Effects 0.000 claims description 2
- 244000144972 livestock Species 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 230000000399 orthopedic effect Effects 0.000 claims description 2
- 239000000816 peptidomimetic Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US873807P | 2007-12-21 | 2007-12-21 | |
| PCT/US2008/014023 WO2009085272A2 (en) | 2007-12-21 | 2008-12-22 | Improved medical devices |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014187605A Division JP2015006440A (ja) | 2007-12-21 | 2014-09-16 | 改良医療デバイス |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011507599A JP2011507599A (ja) | 2011-03-10 |
| JP2011507599A5 true JP2011507599A5 (enExample) | 2013-04-25 |
Family
ID=40466841
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010539515A Pending JP2011507599A (ja) | 2007-12-21 | 2008-12-22 | 改良医療デバイス |
| JP2014187605A Withdrawn JP2015006440A (ja) | 2007-12-21 | 2014-09-16 | 改良医療デバイス |
| JP2016213448A Withdrawn JP2017064431A (ja) | 2007-12-21 | 2016-10-31 | 改良医療デバイス |
| JP2018146805A Pending JP2018198954A (ja) | 2007-12-21 | 2018-08-03 | 改良医療デバイス |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014187605A Withdrawn JP2015006440A (ja) | 2007-12-21 | 2014-09-16 | 改良医療デバイス |
| JP2016213448A Withdrawn JP2017064431A (ja) | 2007-12-21 | 2016-10-31 | 改良医療デバイス |
| JP2018146805A Pending JP2018198954A (ja) | 2007-12-21 | 2018-08-03 | 改良医療デバイス |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US9035037B2 (enExample) |
| EP (1) | EP2234656A2 (enExample) |
| JP (4) | JP2011507599A (enExample) |
| AU (1) | AU2008343843A1 (enExample) |
| CA (1) | CA2710386A1 (enExample) |
| WO (1) | WO2009085272A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101573131B (zh) | 2005-02-03 | 2017-12-01 | 科达治疗有限公司 | 抗‑连接蛋白化合物及其治疗应用 |
| CA2710380A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin 43 poly nucleotide for the treatment of fibrotic conditions |
| US9446031B2 (en) | 2012-01-18 | 2016-09-20 | National University Of Singapore | Compositions and methods for neovascularization |
| MX351881B (es) | 2012-03-01 | 2017-11-01 | Firststring Res Inc | Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act). |
| WO2016029191A2 (en) | 2014-08-22 | 2016-02-25 | Auckland Uniservices Limited | Channel modulators |
| CN105498074B (zh) * | 2015-12-25 | 2017-08-08 | 李雷 | 血管壁修复系统 |
| WO2017190152A1 (en) * | 2016-04-29 | 2017-11-02 | Ocunexus Therapeutics, Inc. | Sustained release drug delivery devices |
| RU2636418C1 (ru) * | 2017-03-16 | 2017-11-23 | Дмитрий Викторович Давыдов | Способ коррекции экзофтальма и имплантат для увеличения объема орбиты в области сформированного костного дефекта при коррекции экзофтальма |
| CN111201247A (zh) | 2017-04-28 | 2020-05-26 | 奥克兰联合服务有限公司 | 治疗方法和新颖构建体 |
| US11911504B2 (en) | 2018-02-02 | 2024-02-27 | Galen Therapeutics Llc | Apparatus and method for protecting neurons and reducing inflammation and scarring |
| US12138293B2 (en) | 2020-10-22 | 2024-11-12 | Xequel Bio, Inc. | Peptide formulations and ophthalmic uses thereof |
| WO2023219655A1 (en) * | 2022-05-13 | 2023-11-16 | University Of Utah Research Foundation | Gja1-20k to limited cardiac arrhythmias |
| US12667586B2 (en) | 2023-03-07 | 2026-06-30 | Glaukos Corporation | Treatments for ocular surface disorders |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1322714C (en) * | 1986-11-14 | 1993-10-05 | Harry N. Antoniades | Wound healing and bone regeneration |
| US4916193A (en) * | 1987-12-17 | 1990-04-10 | Allied-Signal Inc. | Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides |
| US5092877A (en) * | 1988-09-01 | 1992-03-03 | Corvita Corporation | Radially expandable endoprosthesis |
| US5004810A (en) * | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
| US4994071A (en) * | 1989-05-22 | 1991-02-19 | Cordis Corporation | Bifurcating stent apparatus and method |
| US5304121A (en) * | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5166195A (en) * | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
| US5163952A (en) * | 1990-09-14 | 1992-11-17 | Michael Froix | Expandable polymeric stent with memory and delivery apparatus and method |
| US5599352A (en) * | 1992-03-19 | 1997-02-04 | Medtronic, Inc. | Method of making a drug eluting stent |
| GB9206861D0 (en) * | 1992-03-28 | 1992-05-13 | Univ Manchester | Wound healing and treatment of fibrotic disorders |
| US5464650A (en) * | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
| US5857998A (en) * | 1994-06-30 | 1999-01-12 | Boston Scientific Corporation | Stent and therapeutic delivery system |
| US5837313A (en) | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
| US6566339B1 (en) * | 1995-08-04 | 2003-05-20 | Renovo Limited | Pharmaceutical composition |
| GB2304047A (en) * | 1995-08-09 | 1997-03-12 | Univ Manchester | Pharmaceutical compositions containing cytokines |
| AU7248896A (en) * | 1995-10-11 | 1997-04-30 | Chiron Corporation | Combination pdgf, kgf, igf and igfbp for wound healing |
| EP0930876B2 (en) * | 1996-07-22 | 2010-07-07 | Renovo Limited | Use of compounds that promote oestrogenic activity for acclerating the healing of skin wounds |
| GB9702943D0 (en) * | 1997-02-13 | 1997-04-02 | Univ Manchester | Wound healing |
| US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
| US6855505B2 (en) * | 1998-06-26 | 2005-02-15 | Renovo Limited | Method for quantifying TGF-β |
| EP1100529B2 (en) | 1998-07-30 | 2010-08-25 | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health | Thymosin beta 4 promotes wound repair |
| DE19902481A1 (de) * | 1999-01-22 | 2000-07-27 | Signus Medizintechnik Gmbh | Wirbelsäulenersatzkörper |
| US7098190B1 (en) * | 1999-01-27 | 2006-08-29 | Coda Therapeutics Ltd. | Formulations comprising antisense nucleotides to connexins |
| GB9903598D0 (en) * | 1999-02-18 | 1999-04-07 | Univ Manchester | Connective tissue healing |
| US6251136B1 (en) * | 1999-12-08 | 2001-06-26 | Advanced Cardiovascular Systems, Inc. | Method of layering a three-coated stent using pharmacological and polymeric agents |
| US7250397B2 (en) * | 2000-02-23 | 2007-07-31 | Zealand Pharma A/S | Antiarrhythmic peptides |
| JP2005509621A (ja) | 2001-10-17 | 2005-04-14 | ユニバーシティ オブ ウェールズ カレッジ オブ メディスン | ギャップ結合ならびにｅｄｈｆ |
| CN1939529A (zh) * | 2002-01-29 | 2007-04-04 | Wyeth公司 | 用于调节连接蛋白半通道的组合物和方法 |
| US6702850B1 (en) * | 2002-09-30 | 2004-03-09 | Mediplex Corporation Korea | Multi-coated drug-eluting stent for antithrombosis and antirestenosis |
| CN1922320B (zh) * | 2003-12-03 | 2013-04-24 | 科达治疗（新西兰）有限公司 | 靶向连接蛋白的反义化合物及其使用方法 |
| EP1827480B1 (en) | 2004-12-21 | 2016-11-09 | MUSC Foundation For Research Development | Compositions and methods for promoting wound healing and tissue regeneration |
| WO2006084005A2 (en) * | 2005-02-02 | 2006-08-10 | University Of Vermont And State Agricultural College | Emergence of a r-type ca2+channel(cav2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage |
| CN101573131B (zh) * | 2005-02-03 | 2017-12-01 | 科达治疗有限公司 | 抗‑连接蛋白化合物及其治疗应用 |
| CN102920996A (zh) | 2007-12-11 | 2013-02-13 | 科达治疗公司 | 受损伤口愈合的药物组合物 |
-
2008
- 2008-12-22 EP EP08867503A patent/EP2234656A2/en not_active Ceased
- 2008-12-22 CA CA2710386A patent/CA2710386A1/en not_active Abandoned
- 2008-12-22 WO PCT/US2008/014023 patent/WO2009085272A2/en not_active Ceased
- 2008-12-22 JP JP2010539515A patent/JP2011507599A/ja active Pending
- 2008-12-22 AU AU2008343843A patent/AU2008343843A1/en not_active Abandoned
- 2008-12-22 US US12/809,941 patent/US9035037B2/en not_active Expired - Fee Related
-
2014
- 2014-09-16 JP JP2014187605A patent/JP2015006440A/ja not_active Withdrawn
-
2015
- 2015-05-18 US US14/715,282 patent/US9561311B2/en active Active
-
2016
- 2016-10-31 JP JP2016213448A patent/JP2017064431A/ja not_active Withdrawn
-
2017
- 2017-02-03 US US15/424,758 patent/US10251929B2/en not_active Expired - Fee Related
-
2018
- 2018-08-03 JP JP2018146805A patent/JP2018198954A/ja active Pending
-
2019
- 2019-04-08 US US16/378,402 patent/US20190290719A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Parent et al. | Design of calcium phosphate ceramics for drug delivery applications in bone diseases: A review of the parameters affecting the loading and release of the therapeutic substance | |
| ES2848562T3 (es) | Procedimiento indirecto para reparación de tejido articular | |
| JP5114801B2 (ja) | 生体吸収性支持フレームを有するグラフト | |
| CN102231992B (zh) | 用于治疗肌腱和韧带损伤的血小板衍生生长因子的组合物和方法 | |
| US9585988B2 (en) | Anchorage devices comprising an active pharmaceutical ingredient | |
| JP6889193B2 (ja) | 再狭窄の予防または治療のための化合物および方法 | |
| US20050202061A1 (en) | Optimized dosing for drug coated stents | |
| EP1723976A3 (en) | Intraluminal medical devices in combination with therapeutic agents | |
| JP5153340B2 (ja) | 薬剤放出制御組成物および薬剤放出性医療器具 | |
| US20150273119A1 (en) | Formulation comprising anti-scarring agents and biocompatible polymers for medical device coating | |
| EP3056229A3 (en) | The local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque | |
| JP2018198954A (ja) | 改良医療デバイス | |
| MX2010007571A (es) | Endoprotesis eluyente con receptaculo de rapamicina. | |
| ES2987568T3 (es) | Cuerda de terapia de inserción de hilo y aparato de aguja de terapia de inserción de hilo que comprende la misma | |
| DE602005022378D1 (de) | Lokale, vaskuläre Verabreichung von 2-methoxyestradiol in Kombination mit Rapamycin zur Vorbeugung von Restenose nach Gefässverletzungen | |
| Chou et al. | Combination of a biodegradable three-dimensional (3D)–printed cage for mechanical support and nanofibrous membranes for sustainable release of antimicrobial agents for treating the femoral metaphyseal comminuted fracture | |
| JP2011507859A5 (enExample) | ||
| ATE475438T1 (de) | Lokale, vaskuläre verabreichung von etoposide in kombination mit rapamycin zur vorbeugung von restenose nach gefässverletzungen | |
| WO2011031301A2 (en) | Intrapericardial delivery of periostin | |
| US20070129790A1 (en) | Treatment of aneurysms with an implantable polymeric, biodegradable device incorporating a MMP inhibitor | |
| JP2024532867A5 (enExample) | ||
| Kusanagi et al. | Hydrogel-mediated release of basic fibroblast growth factor from a stent-graft accelerates biological fixation with the aortic wall in a porcine model | |
| JP2002512951A5 (enExample) | ||
| KR20150111109A (ko) | 생체적합성 고분자 물질 및 흉터형성 억제약물을 포함하는 의료장치 코팅 제형 | |
| Ward et al. | Strategies to overcome biological barriers to biosensing |